Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?
Sang Kyun SohnJung Min LeeYoungeun JangYunji LeeJihyun NaHee Jeong ChoJoon Ho MoonDong Won BaekPublished in: Expert review of hematology (2024)
Allo-SCT may not be needed, even in young patients with Ph+ALL treated with ponatinib-based IC or combined ponatinib and blinatumomab as frontline therapy. When adopting a ponatinib-based chemo-minimized regimen for induction, allo-SCT is needed with posttransplant ponatinib maintenance. Continuous exposure to ponatinib at pre- or post-transplant is regarded as one of the most important factor for the success of treatment.
Keyphrases
- stem cell transplantation
- acute lymphoblastic leukemia
- chronic myeloid leukemia
- high dose
- end stage renal disease
- newly diagnosed
- allogeneic hematopoietic stem cell transplantation
- chronic kidney disease
- ejection fraction
- middle aged
- locally advanced
- photodynamic therapy
- prognostic factors
- combination therapy
- stem cells
- low dose
- gene expression
- acute myeloid leukemia
- hematopoietic stem cell
- rectal cancer
- patient reported